Aramark (ARMK) 주식 개요
아라마크는 미국 및 전 세계의 교육, 의료, 비즈니스 및 산업, 스포츠, 레저, 교정 고객에게 식품 및 시설 서비스를 제공합니다. 자세히 보기
ARMK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aramark 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$45.26 |
| 52주 최고가 | US$46.88 |
| 52주 최저가 | US$33.71 |
| 베타 | 1.16 |
| 1개월 변동 | 6.37% |
| 3개월 변동 | 16.74% |
| 1년 변동 | 20.24% |
| 3년 변동 | 26.28% |
| 5년 변동 | 22.59% |
| IPO 이후 변동 | 99.38% |
최근 뉴스 및 업데이트
ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow
The analyst price target for Aramark is adjusted modestly higher to $47.63 from $47.16, with analysts pointing to steadier revenue growth assumptions, a slightly higher profit margin outlook, and recent positive research highlighting organic growth and new contract wins as support for the change. Analyst Commentary Recent research around Aramark centers on organic growth trends, contract wins and how these factors feed into valuation.ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow
Aramark's analyst price target has inched higher, with a modest fair value adjustment to about $47.16 as analysts highlight stronger than expected organic growth trends, a new RWJ Barnabas Health contract scheduled to ramp up in 2026, and generally constructive sector views as key supports. Analyst Commentary Bullish analysts are generally constructive on Aramark, pointing to recent price target increases and renewed coverage with higher fair value estimates.ARMK: New Contracts And Buybacks Will Support Future Free Cash Flow
Analysts have raised the implied fair value for Aramark by about $0.47 to $47.09, reflecting updated assumptions around revenue growth, profitability and future P/E in the context of a recent wave of higher $50 price targets across research reports. Analyst Commentary Recent research updates cluster around a US$50 price target, with several firms lifting their views in quick succession.Aramark's Growth Story Isn't Over Yet
Mar 24Recent updates
ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow
The analyst price target for Aramark is adjusted modestly higher to $47.63 from $47.16, with analysts pointing to steadier revenue growth assumptions, a slightly higher profit margin outlook, and recent positive research highlighting organic growth and new contract wins as support for the change. Analyst Commentary Recent research around Aramark centers on organic growth trends, contract wins and how these factors feed into valuation.ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow
Aramark's analyst price target has inched higher, with a modest fair value adjustment to about $47.16 as analysts highlight stronger than expected organic growth trends, a new RWJ Barnabas Health contract scheduled to ramp up in 2026, and generally constructive sector views as key supports. Analyst Commentary Bullish analysts are generally constructive on Aramark, pointing to recent price target increases and renewed coverage with higher fair value estimates.ARMK: New Contracts And Buybacks Will Support Future Free Cash Flow
Analysts have raised the implied fair value for Aramark by about $0.47 to $47.09, reflecting updated assumptions around revenue growth, profitability and future P/E in the context of a recent wave of higher $50 price targets across research reports. Analyst Commentary Recent research updates cluster around a US$50 price target, with several firms lifting their views in quick succession.Aramark's Growth Story Isn't Over Yet
Mar 24ARMK: Contract Wins And Buybacks Will Support Higher FY26 Cash Generation
Narrative Update Analysts have lifted their average price target on Aramark by about $3 to $50, citing stronger than expected organic growth and increased visibility from a new RWJ Barnabas Health contract, as well as broader optimism regarding revenue, EPS and free cash flow trends into 2026. Analyst Commentary Recent Street research on Aramark centers on higher price targets and fresh coverage, with most of the discussion tied to organic growth trends, contract wins and expectations for earnings and cash flow through 2026.ARMK: Contract Wins And Buybacks Will Support Stronger FY26 Earnings Delivery
Analysts have lifted their average Aramark price target from about $44.60 to roughly $46.63. The updated views factor in recent organic growth trends and expectations for future contract contributions and earnings power.ARMK: Contract Timing Delays Will Support Stronger FY26 Earnings Delivery
Narrative Update on Aramark Analysts have trimmed their Aramark price target to US$44 from US$49, citing a shift in expected revenue timing as client driven delays in new contract starts across Corrections, Workplace Experience, and Healthcare push more of the projected contribution into FY26. They continue to model a similar long term P/E and margin profile.ARMK: Contract Timing Delays Will Create FY26 Margin Upside Scenario
Analysts recently trimmed their Aramark price target to $44 from $49, pointing to what they describe as strong underlying business momentum, but also to client driven timing delays on new contract starts that are expected to shift some revenue and margin impact into FY26. Analyst Commentary Bullish Takeaways Bullish analysts see the lower US$44 price target as reflecting updated timing rather than a change in their view of Aramark’s underlying business momentum.Is Aramark (NYSE:ARMK) Worth US$38.0 Based On Its Intrinsic Value?
Jan 06
ARMK: Delayed Contract Ramps Will Drive Stronger Earnings Setup In Fiscal 2026
Analysts have modestly reduced their price target on Aramark to approximately $44 from about $49, citing strong underlying business momentum but near term revenue and earnings pressure from client driven timing delays in new contract starts, which are now expected to shift more meaningfully into FY26. Analyst Commentary Bullish Takeaways Bullish analysts highlight that underlying business momentum remains solid across key operating segments, supporting confidence in the company’s long term growth trajectory despite near term volatility.ARMK: Delayed Contract Starts Will Support Stronger Earnings Momentum In Fiscal 2026
Analysts have trimmed their price target on Aramark to $44 from $49, reflecting expectations for strong underlying momentum but a near term zig zag in revenue and margins as client driven contract start delays shift more growth into FY26. Analyst Commentary Street research indicates that the recent price target reduction reflects adjustments to the timing of expected growth rather than a reset of the long term thesis.ARMK: Delayed Contract Starts Will Shift Earnings Momentum Toward Fiscal 2026
Analysts have modestly raised their Aramark price target to approximately $44.60 per share from about $44.43, citing strong underlying business momentum despite near term revenue and earnings pressure from client driven delays in new contract starts, which are now expected to shift growth into FY26. Analyst Commentary Recent Street research highlights a mixed, but generally constructive, view on Aramark, with analysts fine tuning their expectations to reflect both the strength of the core business and the impact of timing related revenue shifts.Earnings Miss: Aramark Missed EPS By 19% And Analysts Are Revising Their Forecasts
Nov 20ARMK: Delayed Contract Starts Will Drive Revenue Expansion Beyond Fiscal 2025
Aramark's analyst price target has been revised downward from $45.10 to $44.43, as analysts factor in strong underlying business momentum while adjusting for delays in revenue and earnings due to client-driven timing in new contract starts. Analyst Commentary Analyst perspectives on Aramark reflect a mix of optimism about core business trends and caution around near-term uncertainty driven by client timing.What Is Aramark's (NYSE:ARMK) Share Price Doing?
Oct 01Sports, Education And Healthcare Wins Will Expand Global Reach
Aramark’s fair value estimate was slightly reduced as a result of a deteriorating net profit margin and an increased future P/E, indicating weaker profitability and pricier valuation. What's in the News Aramark expanded its presence in NCAA collegiate sports by delivering customized hospitality experiences at over 30 football stadiums and secured new partnerships with Arizona State University and the University of Nebraska.Is Aramark (NYSE:ARMK) Using Too Much Debt?
Jul 07Is It Time To Consider Buying Aramark (NYSE:ARMK)?
Jun 16Aramark's (NYSE:ARMK) 25% Jump Shows Its Popularity With Investors
May 08Aramark Is A 'BUY', But With Some Details (Rating Upgrade)
Apr 28Aramark: Rating Downgrade To Hold As I See Risk To The Company Meeting FY25 Guidance
Feb 08Aramark: Robust FY25 Outlook
Nov 22Aramark: Switching To Sodexo After M&A Talk
Sep 27
Calculated Expansions And Efficiency Gains Propel Revenue And Profitability Forward
Aramark's focus on new client acquisition and retention promises enhanced revenue growth and improved profitability margins through strategic growth initiatives.Aramark: Visible Path To Both Revenue And EBIT Growth
Jun 30주주 수익률
| ARMK | US Hospitality | US 시장 | |
|---|---|---|---|
| 7D | -0.4% | 0.5% | 1.8% |
| 1Y | 20.2% | 1.7% | 29.8% |
수익률 대 산업: ARMK은 지난 1년 동안 1.7%의 수익을 기록한 US Hospitality 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: ARMK은 지난 1년 동안 29.8%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| ARMK volatility | |
|---|---|
| ARMK Average Weekly Movement | 4.2% |
| Hospitality Industry Average Movement | 7.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: ARMK는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ARMK의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1959 | 278,390 | John Zillmer | www.aramark.com |
아라마크는 미국 및 전 세계의 교육, 의료, 비즈니스 및 산업, 스포츠, 레저, 교정 고객에게 식품 및 시설 서비스를 제공합니다. 이 회사는 미국 식품 및 지원 서비스 부문과 국제 식품 및 지원 서비스 부문의 두 가지 부문으로 운영되고 있습니다. 이 회사는 식당, 케이터링, 식품 서비스 관리, 편의 중심의 소매 서비스 등 식품 관련 관리 서비스, 환자 식품 및 영양, 소매 식품, 환경 서비스, 조달 서비스 등 비임상 식품 및 식품 관련 지원 서비스, 공장 운영 및 유지보수, 관리/하우스키핑, 에너지 관리, 부지 유지, 자본 프로젝트 관리 서비스 등을 제공합니다.
Aramark 기초 지표 요약
| ARMK 기초 통계 | |
|---|---|
| 시가총액 | US$11.77b |
| 순이익 (TTM) | US$316.94m |
| 매출 (TTM) | US$18.79b |
37.5x
주가수익비율(P/E)0.6x
주가매출비율(P/S)ARMK는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ARMK 손익계산서 (TTM) | |
|---|---|
| 매출 | US$18.79b |
| 매출원가 | US$15.88b |
| 총이익 | US$2.90b |
| 기타 비용 | US$2.59b |
| 순이익 | US$316.94m |
최근 보고된 실적
Jan 02, 2026
다음 실적 발표일
May 12, 2026
| 주당순이익(EPS) | 1.21 |
| 총이익률 | 15.46% |
| 순이익률 | 1.69% |
| 부채/자본 비율 | 191.5% |
ARMK의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
1.1%
현재 배당 수익률37%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/05 10:21 |
| 종가 | 2026/05/05 00:00 |
| 수익 | 2026/01/02 |
| 연간 수익 | 2025/10/03 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Aramark는 23명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Andrew Wittmann | Baird |
| Manav Patnaik | Barclays |
| Stuart Gordon | Berenberg |